nach oben

Journal of Neural Transmission

Erschienen in:

01.02.2016 | Translational Neurosciences - Review article

Mitochondrial mechanisms of redox cycling agents implicated in Parkinson’s disease

verfasst von: Pamela Lopert, Manisha Patel

Erschienen in: Journal of Neural Transmission | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Environmental agents have been implicated in Parkinson’s disease (PD) based on epidemiological studies and the ability of toxicants to replicate features of PD. However, the precise mechanisms by which toxicants induce dopaminergic toxicity observed in the idiopathic form of PD remain to be fully understood. The roles of ROS and mitochondria are strongly suggested in the mechanisms by which these toxicants exert dopaminergic toxicity. There are marked differences and similarities shared by the toxicants in increasing steady-state levels of mitochondrial ROS. Furthermore, toxicants increase steady-state mitochondrial ROS levels by stimulating the production, inhibiting the antioxidant pathways of both. This review will focus on the role of mitochondria and ROS in PD associated with environmental exposures to redox-based toxicants.

Abou-Sleiman PM, Muqit MM, Wood NW (2006) Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nat Rev Neurosci 7:207–219PubMedCrossRef

Adams JD, Klaidman LK, Cadenas E (1992) MPP+ redox cycling: a new mechanism involving hydride transfer. Ann N Y Acad Sci 648:239–240PubMedCrossRef

Ahmadi FA, Linseman DA, Grammatopoulos TN, Jones SM, Bouchard RJ, Freed CR, Heidenreich KA, Zawada WM (2003) The pesticide rotenone induces caspase-3-mediated apoptosis in ventral mesencephalic dopaminergic neurons. J Neurochem 87:914–921PubMedCrossRef

Bains JS, Shaw CA (1997) Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Brain Res Rev 25:335–358PubMedCrossRef

Barlow BK, Lee DW, Cory-Slechta DA, Opanashuk LA (2005) Modulation of antioxidant defense systems by the environmental pesticide maneb in dopaminergic cells. Neurotoxicology 26:63–75PubMedCrossRef

Baynes JW (1991) Role of oxidative stress in development of complications in diabetes. Diabetes 40:405–412PubMedCrossRef

Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 3:1301–1306PubMedCrossRef

Betarbet R, Sherer TB, Greenamyre JT (2002) Animal models of Parkinson’s disease. BioEssays 24:308–318PubMedCrossRef

Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson’s disease. Prog Neurobiol 65:135–172PubMedCrossRef

Bonneh-Barkay D, Reaney SH, Langston WJ, Di Monte DA (2005) Redox cycling of the herbicide paraquat in microglial cultures. Brain Res Mol Brain Res 134:52–56PubMedCrossRef

Bove J, Perier C (2012) Neurotoxin-based models of Parkinson’s disease. Neuroscience 211:51–76PubMedCrossRef

Boveris A, Chance B (1973) The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem J 134:707–716PubMedCentralPubMedCrossRef

Brooks AI, Chadwick CA, Gelbard HA, Cory-Slechta DA, Federoff HJ (1999) Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res 823:1–10PubMedCrossRef

Cadenas E, Davies KJ (2000) Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 29:222–230PubMedCrossRef

Callio J, Oury TD, Chu CT (2005) Manganese superoxide dismutase protects against 6-hydroxydopamine injury in mouse brains. J Biol Chem 280:18536–18542PubMedCentralPubMedCrossRef

Castello PR, Drechsel DA, Patel M (2007) Mitochondria are a major source of paraquat-induced reactive oxygen species production in the brain. J Biol Chem 282:14186–14193PubMedCentralPubMedCrossRef

Chacon JN, Chedekel MR, Land EJ, Truscott TG (1987) Chemically induced Parkinson’s disease: intermediates in the oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to the 1-methyl-4-phenyl-pyridinium ion. Biochem Biophys Res Commun 144:957–964PubMedCrossRef

Chandel NS, Budinger GR (2007) The cellular basis for diverse responses to oxygen. Free Radic Biol Med 42:165–174PubMedCrossRef

Chen Y, Cai J, Murphy TJ, Jones DP (2002) Overexpressed human mitochondrial thioredoxin confers resistance to oxidant-induced apoptosis in human osteosarcoma cells. J Biol Chem 277:33242–33248PubMedCrossRef

Cherubini A, Ruggiero C, Polidori MC, Mecocci P (2005) Potential markers of oxidative stress in stroke. Free Radic Biol Med 39:841–852PubMedCrossRef

Cicchetti F, Drouin-Ouellet J, Gross RE (2009) Environmental toxins and Parkinson’s disease: what have we learned from pesticide-induced animal models? Trends Pharmacol Sci 30:475–483PubMedCrossRef

Cleeter MW, Cooper JM, Schapira AH (1992) Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem 58:786–789PubMedCrossRef

Clejan L, Cederbaum AI (1989) Synergistic interactions between NADPH-cytochrome P-450 reductase, paraquat, and iron in the generation of active oxygen radicals. Biochem Pharmacol 38:1779–1786PubMedCrossRef

Collins Y, Chouchani ET, James AM, Menger KE, Cocheme HM, Murphy MP (2012) Mitochondrial redox signalling at a glance. J Cell Sci 125:801–806PubMedCrossRef

Conrad M, Jakupoglu C, Moreno SG, Lippl S, Banjac A, Schneider M, Beck H, Hatzopoulos AK, Just U, Sinowatz F, Schmahl W, Chien KR, Wurst W, Bornkamm GW, Brielmeier M (2004) Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol Cell Biol 24:9414–9423PubMedCentralPubMedCrossRef

Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B (2009) Parkinson’s disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol 169:919–926PubMedCentralPubMedCrossRef

Curtius HC, Wolfensberger M, Steinmann B, Redweik U, Siegfried J (1974) Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus. J Chromatogr 99:529–540PubMedCrossRef

Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39:889–909PubMedCrossRef

Dawson TM, Dawson VL (2003) Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J Clin Invest 111:145–151PubMedCentralPubMedCrossRef

Day BJ, Shawen S, Liochev SI, Crapo JD (1995) A metalloporphyrin superoxide dismutase mimetic protects against paraquat-induced endothelial cell injury, in vitro. J Pharmacol Exp Ther 275:1227–1232PubMed

Day BJ, Patel M, Calavetta L, Chang LY, Stamler JS (1999) A mechanism of paraquat toxicity involving nitric oxide synthase. Proc Natl Acad Sci USA 96:12760–12765PubMedCentralPubMedCrossRef

Deumens R, Blokland A, Prickaerts J (2002) Modeling Parkinson’s disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175:303–317PubMedCrossRef

Dhillon AS, Tarbutton GL, Levin JL, Plotkin GM, Lowry LK, Nalbone JT, Shepherd S (2008) Pesticide/environmental exposures and Parkinson’s disease in East Texas. J Agromedicine 13:37–48PubMedCrossRef

Dickinson DA, Forman HJ (2002) Cellular glutathione and thiols metabolism. Biochem Pharmacol 64:1019–1026PubMedCrossRef

Dinis-Oliveira RJ, Remiao F, Carmo H, Duarte JA, Navarro AS, Bastos ML, Carvalho F (2006) Paraquat exposure as an etiological factor of Parkinson’s disease. Neurotoxicology 27:1110–1122PubMedCrossRef

Domico LM, Zeevalk GD, Bernard LP, Cooper KR (2006) Acute neurotoxic effects of mancozeb and maneb in mesencephalic neuronal cultures are associated with mitochondrial dysfunction. Neurotoxicology 27:816–825PubMedCrossRef

Drechsel DA, Patel M (2008) Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson’s disease. Free Radic Biol Med 44:1873–1886PubMedCentralPubMedCrossRef

Drechsel DA, Patel M (2009a) Chapter 21 paraquat-induced production of reactive oxygen species in brain mitochondria. Methods Enzymol 456:381–393PubMedCrossRef

Drechsel DA, Patel M (2009b) Differential contribution of the mitochondrial respiratory chain complexes to reactive oxygen species production by redox cycling agents implicated in parkinsonism. Toxicol Sci 112:427–434PubMedCentralPubMedCrossRef

Drechsel DA, Patel M (2010) Respiration-dependent H₂O₂ removal in brain mitochondria via the thioredoxin/peroxiredoxin system. J Biol Chem 285:27850–27858PubMedCentralPubMedCrossRef

Fahn S (2003) Description of Parkinson’s disease as a clinical syndrome. Ann N Y Acad Sci 991:1–14PubMedCrossRef

Fahn S, Sulzer D (2004) Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 1:139–154PubMedCentralPubMedCrossRef

Floor E, Wetzel MG (1998) Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 70:268–275PubMedCrossRef

Forno LS, DeLanney LE, Irwin I, Langston JW (1996) Electron microscopy of Lewy bodies in the amygdala-parahippocampal region. Comparison with inclusion bodies in the MPTP-treated squirrel monkey. Adv Neurol 69:217–228PubMed

Fukushima T, Yamada K, Isobe A, Shiwaku K, Yamane Y (1993) Mechanism of cytotoxicity of paraquat. I. NADH oxidation and paraquat radical formation via complex I. Exp Toxicol Pathol 45:345–349PubMedCrossRef

Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752–1761PubMedCentralPubMedCrossRef

Giordano FJ (2005) Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 115:500–508PubMedCentralPubMedCrossRef

Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ (1998) The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology 50:1346–1350PubMedCrossRef

Graham DG (1984) Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson’s disease. Neurotoxicology 5:83–95PubMed

Grant H, Lantos PL, Parkinson C (1980) Cerebral damage in paraquat poisoning. Histopathology 4:185–195PubMedCrossRef

Guilarte TR (2010) Manganese and Parkinson’s disease: a critical review and new findings. Environ Health Perspect 118:1071–1080PubMedCentralPubMedCrossRef

Gutteridge JM, Halliwell B (2010) Antioxidants: molecules, medicines, and myths. Biochem Biophys Res Commun 393:561–564PubMedCrossRef

Haas RH, Nasirian F, Nakano K, Ward D, Pay M, Hill R, Shults CW (1995) Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson’s disease. Ann Neurol 37:714–722PubMedCrossRef

Haller HL, Goodhue LD, Jones Howard A (1942) The constituents of derris and other rotenone-bearing plants. Chem Rev 30(1):33–48CrossRef

Halliwell B, Gutteridge J (2007) Free radicals in biology and medicine, 4th edn. Oxford University Press, New York

Hanschmann EM, Godoy JR, Berndt C, Hudemann C, Lillig CH (2013) Thioredoxins, glutaredoxins and peroxiredoxins—molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling. Antioxid Redox Signal 19(13):1539–1605PubMedCentralPubMedCrossRef

Hasegawa E, Takeshige K, Oishi T, Murai Y, Minakami S (1990) 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem Biophys Res Commun 170:1049–1055PubMedCrossRef

Heikkila RE, Hess A, Duvoisin RC (1984) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224:1451–1453PubMedCrossRef

Henchcliffe C, Beal MF (2008) Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 4:600–609PubMedCrossRef

Hertzman C, Wiens M, Bowering D, Snow B, Calne D (1990) Parkinson’s disease: a case-control study of occupational and environmental risk factors. Am J Ind Med 17:349–355PubMedCrossRef

Hughes JT (1988) Brain damage due to paraquat poisoning: a fatal case with neuropathological examination of the brain. Neurotoxicology 9:243–248PubMed

Javitch JA, D’Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82:2173–2177PubMedCentralPubMedCrossRef

Jomova K, Valko M (2011) Advances in metal-induced oxidative stress and human disease. Toxicology 283:65–87PubMedCrossRef

Jones DP, Go YM (2010) Redox compartmentalization and cellular stress. Diabetes Obes Metab 12(Suppl 2):116–125PubMedCentralPubMedCrossRef

Jones GM, Vale JA (2000) Mechanisms of toxicity, clinical features, and management of diquat poisoning: a review. J Toxicol Clin Toxicol 38:123–128PubMedCrossRef

Kachroo A, Irizarry MC, Schwarzschild MA (2010) Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Exp Neurol 223:657–661PubMedCentralPubMedCrossRef

Karuppagounder SS, Ahuja M, Buabeid M, Parameshwaran K, Abdel-Rehman E, Suppiramaniam V, Dhanasekaran M (2012) Investigate the chronic neurotoxic effects of diquat. Neurochem Res 37:1102–1111PubMedCrossRef

Klaidman LK, Adams JD Jr, Leung AC, Kim SS, Cadenas E (1993) Redox cycling of MPP+: evidence for a new mechanism involving hydride transfer with xanthine oxidase, aldehyde dehydrogenase, and lipoamide dehydrogenase. Free Radic Biol Med 15:169–179PubMedCrossRef

Kulich SM, Horbinski C, Patel M, Chu CT (2007) 6-Hydroxydopamine induces mitochondrial ERK activation. Free Radic Biol Med 43:372–383PubMedCentralPubMedCrossRef

Lang AE, Lozano AM (1998) Parkinson’s disease. First of two parts. N Engl J Med 339:1044–1053PubMedCrossRef

Lang CA, Wu WK, Chen T, Mills BJ (1989) Blood glutathione: a biochemical index of life span enhancement in the diet restricted Lobund-Wistar rat. Prog Clin Biol Res 287:241–246PubMed

Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979–980PubMedCrossRef

Liang LP, Kavanagh TJ, Patel M (2013) Glutathione deficiency in Gclm null mice results in complex I inhibition and dopamine depletion following paraquat administration. Toxicol Sci 134:366–373PubMedCentralPubMedCrossRef

Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787–795PubMedCrossRef

Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, Chen RC (1997) Environmental risk factors and Parkinson’s disease: a case-control study in Taiwan. Neurology 48:1583–1588PubMedCrossRef

Logroscino G (2005) The role of early life environmental risk factors in Parkinson disease: what is the evidence? Environ Health Perspect 113:1234–1238PubMedCentralPubMedCrossRef

Lomaestro BM, Malone M (1995) Glutathione in health and disease: pharmacotherapeutic issues. Ann Pharmacother 29:1263–1273PubMed

Lopert P, Day BJ, Patel M (2012) Thioredoxin reductase deficiency potentiates oxidative stress, mitochondrial dysfunction and cell death in dopaminergic cells. PLoS One 7:e50683PubMedCentralPubMedCrossRef

Martin HL, Teismann P (2009) Glutathione–a review on its role and significance in Parkinson’s disease. Faseb J 23:3263–3272PubMedCrossRef

McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, Di Monte DA (2002) Environmental risk factors and Parkinson’s disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 10:119–127PubMedCrossRef

Morato GS, Lemos T, Takahashi RN (1989) Acute exposure to maneb alters some behavioral functions in the mouse. Neurotoxicol Teratol 11:421–425PubMedCrossRef

Murphy MP (2009) How mitochondria produce reactive oxygen species. Biochem J 417:1–13PubMedCentralPubMedCrossRef

Nicklas WJ, Vyas I, Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36:2503–2508PubMedCrossRef

Nonn L, Williams RR, Erickson RP, Powis G (2003) The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Mol Cell Biol 23:916–922PubMedCentralPubMedCrossRef

Parker WD Jr, Boyson SJ, Parks JK (1989) Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol 26:719–723PubMedCrossRef

Parker WD Jr, Parks JK, Swerdlow RH (2008) Complex I deficiency in Parkinson’s disease frontal cortex. Brain Res 1189:215–218PubMedCentralPubMedCrossRef

Parkinson J (2002) An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci 14:223–236 (discussion 222)PubMedCrossRef

Patel M, Day BJ (1999) Metalloporphyrin class of therapeutic catalytic antioxidants. Trends Pharmacol Sci 20:359–364PubMedCrossRef

Perry TL, Godin DV, Hansen S (1982) Parkinson’s disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33:305–310PubMedCrossRef

Price LA, Newman KJ, Clague AE, Wilson PR, Wenck DJ (1995) Paraquat and diquat interference in the analysis of creatinine by the Jaffe reaction. Pathology 27:154–156PubMedCrossRef

Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS (2001) Environmental risk factors and Parkinson’s disease: a metaanalysis. Environ Res 86:122–127PubMedCrossRef

Roede JR, Jones DP (2014) Thiol-reactivity of the fungicide maneb. Redox Biol 2:651–655PubMedCentralPubMedCrossRef

Roede JR, Hansen JM, Go YM, Jones DP (2011) Maneb and paraquat-mediated neurotoxicity: involvement of peroxiredoxin/thioredoxin system. Toxicol Sci 121:368–375PubMedCentralPubMedCrossRef

Rybnikova E, Damdimopoulos AE, Gustafsson JA, Spyrou G, Pelto-Huikko M (2000) Expression of novel antioxidant thioredoxin-2 in the rat brain. Eur J Neurosci 12:1669–1678PubMedCrossRef

Sato S, Hattori N (2011) Genetic mutations and mitochondrial toxins shed new light on the pathogenesis of Parkinson’s disease. Parkinsons Dis 2011:979231PubMedCentralPubMed

Sechi GP, Agnetti V, Piredda M, Canu M, Deserra F, Omar HA, Rosati G (1992) Acute and persistent parkinsonism after use of diquat. Neurology 42:261–263PubMedCrossRef

Shastry BS (2003) Neurodegenerative disorders of protein aggregation. Neurochem Int 43:1–7PubMedCrossRef

Shaw CA, Pasqualotto BA, Curry K (1996) Glutathione-induced sodium currents in neocortex. NeuroReport 7:1149–1152PubMedCrossRef

Sheeran FL, Rydstrom J, Shakhparonov MI, Pestov NB, Pepe S (2010) Diminished NADPH transhydrogenase activity and mitochondrial redox regulation in human failing myocardium. Biochim Biophys Acta 1797:1138–1148PubMedCrossRef

Shimizu K, Ohtaki K, Matsubara K, Aoyama K, Uezono T, Saito O, Suno M, Ogawa K, Hayase N, Kimura K, Shiono H (2001) Carrier-mediated processes in blood–brain barrier penetration and neural uptake of paraquat. Brain Res 906:135–142PubMedCrossRef

Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994) Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36:348–355PubMedCrossRef

Smith LL (1982) Young scientists award lecture 1981: the identification of an accumulation system for diamines and polyamines into the lung and its relevance to paraquat toxicity. Arch Toxicol Suppl 5:1–14PubMedCrossRef

Smith Y, Wichmann T, Factor SA, DeLong MR (2011) Parkinson’s disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology 37:213–246PubMedCentralPubMedCrossRef

Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease. Neurosci Lett 142:128–130PubMedCrossRef

Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95:6469–6473PubMedCentralPubMedCrossRef

Subramaniam SR, Chesselet MF (2013) Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Prog Neurobiol 106–107:17–32PubMedCrossRef

Tait SW, Green DR (2012) Mitochondria and cell signalling. J Cell Sci 125:807–815PubMedCentralPubMedCrossRef

Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DM, Blair A, Sandler DP, Langston JW (2011) Rotenone, paraquat, and Parkinson’s disease. Environ Health Perspect 119:866–872PubMedCentralPubMedCrossRef

Tomita M (1991) Comparison of one-electron reduction activity against the bipyridylium herbicides, paraquat and diquat, in microsomal and mitochondrial fractions of liver, lung and kidney (in vitro). Biochem Pharmacol 42:303–309PubMedCrossRef

Turrens JF (2003) Mitochondrial formation of reactive oxygen species. J Physiol 552:335–344PubMedCentralPubMedCrossRef

Uversky VN (2004) Neurotoxicant-induced animal models of Parkinson’s disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res 318:225–241PubMedCrossRef

Veal EA, Day AM, Morgan BA (2007) Hydrogen peroxide sensing and signaling. Mol Cell 26:1–14PubMedCrossRef

Yang Y, Dieter MZ, Chen Y, Shertzer HG, Nebert DW, Dalton TP (2002) Initial characterization of the glutamate-cysteine ligase modifier subunit Gclm(−/−) knockout mouse. Novel model system for a severely compromised oxidative stress response. J Biol Chem 277:49446–49452PubMedCrossRef

Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A 93:2696–2701PubMedCentralPubMedCrossRef

Yoshino H, Nakagawa-Hattori Y, Kondo T, Mizuno Y (1992) Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson’s disease. J Neural Transm Park Dis Dement Sect 4:27–34PubMedCrossRef

Zeevalk GD, Razmpour R, Bernard LP (2008) Glutathione and Parkinson’s disease: is this the elephant in the room? Biomed Pharmacother 62:236–249PubMedCrossRef

Zhang J, Fitsanakis VA, Gu G, Jing D, Ao M, Amarnath V, Montine TJ (2003) Manganese ethylene-bis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction. J Neurochem 84:336–346PubMedCrossRef

Ziemssen T, Reichmann H (2007) Non-motor dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 13:323–332PubMedCrossRef

Titel: Mitochondrial mechanisms of redox cycling agents implicated in Parkinson’s disease
verfasst von: Pamela Lopert
Manisha Patel
Publikationsdatum: 01.02.2016
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 2/2016
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-015-1386-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Cerebrovascular and mitochondrial abnormalities in Alzheimer’s disease: a brief overview

Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets

Mitochondria: old and new target in brain research

Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression